Latest Conference Articles

Rethinking Initial Management of Patients With Brain Metastasis and HER2 Breast Cancer

Lapatinib and capecitabine is a reasonable approach in a well-informed patient with brain metastasis and HER2+ breast cancer

Two Studies Herald New Era in Melanoma Therapy

New treatment approaches that improve overall survival for patients with late-stage melanoma spotlighted

Three-Year Imatinib Regimen Delivers Optimal GIST Treatment

3 years of treatment with imatinib (Gleevec) after surgery in patients with high-risk GIST improved overall and recurrence-free survival

Pemetrexed Maintenance Improves Progression-Free Survival in Patients With NSCLC

Continuation maintenance with pemetrexed (Alimta) improves progression-free survival in patients with advanced nonsquamous non–small cell lung cancer

Dr. Wolchok Describes the Immunotherapy Ipilimumab

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab

Dr. Kris on the Use of Genetic Testing in Lung Cancer

Dr. Kris From Memorial Sloan-Kettering Cancer Center on the Use of Genetic Testing in Lung Cancer

MEK and BRAF Therapy Combo Promising for Advanced Melanoma

The combination of the MEK inhibitor GSK212 and the oral BRAF inhibitor GSK436 resulted in anti-tumor activity in patients with advanced melanoma

Dr. Virgo on Survivorship Care Training & Policies

Dr. Katherine Virgo from the American Cancer Society Discusses Survivorship Care Training & Policies

Dr. Hoos on the Patients That Respond to Ipilimumab

Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab

Dr. Chapman Describes the Side Effects of Vemurafenib

Dr. Paul Chapman from Memorial Sloan-Kettering Cancer Center Describes the Side Effects of Vemurafenib

Dr. Tsimberidou Discusses Improving Care

Apostolia M. Tsimberidou, MD, PhD, from MD Anderson Cancer Center discusses improving cancer care.

Dr. Cella on Patient Assessment Reference Scores

Dr. Cella from Northwestern University Feinberg School of Medicine on Patient Assessment Reference Scores

Genetic Testing Delivers Personalized Lung Cancer Therapy

Taking a page from breast cancer treatment, clinicians managing lung cancer patients can now detect mutations that drive the development of lung cancer

NKTR-102 Shows Promise in Phase II Trial

Metastatic breast cancer patients with demonstrated disease progression after taxane therapy face an uphill battle in fighting their disease.

Circulating Tumor Cells Show Promise as Surrogate for Survival in Prostate Cancer Trials

Prostate cancer research lacks surrogate biomarkers for survival that could hasten the study and approval of new medications.

Regional Radiation Therapy Improves Outcomes in Early Breast Cancer

Radiation therapy directed to the regional lymph nodes of women with early-stage breast cancer reduced distant disease recurrence

Amonafide Plus Cytarabine Fails To Meet Primary Endpoint

Amonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data

High-Dose Methotrexate Better for ALL

High doses of methotrexate increases EFS for children and young adults

Molecular Profiling Boosts Targeted Therapies in Phase I Trial

Matching patients with targeted therapies based on molecular profile results in superior clinical outcomes

Dr. Joensuu on the Imatinib for High-Risk GIST Trial

Dr. Heikki Joensuu from the Helsinki University Central Hospital Summarizes the Imatinib for High-Risk high-risk gastrointestinal stromal tumors (GIST) Trial

Tim Turnham Discusses Melanoma Treatment Advances

Tim Turnham the Executive Director of the Melanoma Research Foundation Discusses Melanoma Treatment Advances

Investors Taking Stock of Key ASCO Abstracts

Oncology specialists, biopharmaceutical analysts and investors all await the latest research news from the upcoming ASCO annual meeting

Genetic Analysis Yields Biomarker for Neuropathy

A genetic analysis resulted in the discovery of the first predictive biomarker for taxane-induced peripheral neuropathy

Cabozantinib (XL184) Demonstrates Antitumor Activity and Reduces or Eliminates Bone Metastases in Multiple Cancers

Cabozantinib (XL184), an investigational oral tyrosine kinase inhibitor, demonstrated antitumor activity in multiple types of advanced solid tumors.

Study Results Show Ovarian Cancer Deaths Are Not Reduced by Early-Detection Screening Methods

The risk of dying from ovarian cancer was not reduced when women received CA-125 blood testing and transvaginal ultrasound

Study Confirms Extending Testing to Every 3 Years in Women Who Test Negative for the HPV Virus

A large-scale study of HPV testing and Pap smear for cervical cancer screening confirms that women can safely extend screening intervals from 1 to 3 years.

PSA Found to Be Highly Predictive of Long-Term Risk of Death From Prostate Cancer

Prostate-specific antigen (PSA) levels can accurately predict the risk of developing metastasis or death from prostate cancer up to 30 years later

Among Women at High Risk for Breast Cancer, Study Finds Smoking, Not Moderate Alcohol Use, Increases Risk of Common Cancers

A prospective study analyzed the risk of contracting common cancers based on baseline self-reporting data on smoking, alcohol use, and physical activity

Stay tuned for Live Conference Coverage from ASCO 2011

ASCO 2011, June 3-7, 2011 McCormick Place, Chicago, IL

Donna Berry on Winning Researcher Award

Donna Berry on the Distinguished Researcher Award and Her Advice to Researchers